The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ZNTL | -52.22% | -97.26% | -51.26% | -94% |
| S&P | +16.49% | +84.25% | +12.99% | +175% |
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin D. Bunker on December 23, 2014 and is headquartered in New York, NY.
A rash of insider selling meant the stock gave back some of its gains from last week.
In less than two months, the company's share price has nearly tripled since its IPO. Is it too late to get in on the fun?
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.16M | 50.2% |
| Gross Margin | 98.82% | 0.0% |
| Market Cap | $108.92M | -58.4% |
| Market Cap / Employee | $0.66M | 0.0% |
| Employees | 166 | -1.2% |
| Net Income | -$26.69M | 33.5% |
| EBITDA | -$33.57M | 34.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $39.07M | -5.4% |
| Accounts Receivable | $0.00M | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $36.71M | -9.3% |
| Short Term Debt | $3.75M | 33.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -38.39% | -3.8% |
| Return On Invested Capital | -46.24% | 5.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$26.96M | 38.8% |
| Operating Free Cash Flow | -$26.96M | 38.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.61 | 0.34 | 0.28 | 0.40 | -41.99% |
| Price to Sales | 3.20 | 4.24 | 3.11 | 4.05 | -37.15% |
| Price to Tangible Book Value | 0.61 | 0.34 | 0.28 | 0.40 | -42.55% |
| Enterprise Value to EBITDA | 2.46 | 4.94 | 4.98 | 3.91 | 131.64% |
| Return on Equity | -42.8% | -59.5% | -49.5% | -49.2% | 14.68% |
| Total Debt | $42.65M | $38.65M | $41.32M | $40.46M | -6.49% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
